MR-Linac for Head and Neck SBRT

NCT ID: NCT04809792

Last Updated: 2023-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2030-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the feasibility and safety of using MR-guided adaptive Head and Neck stereotactic radiotherapy (SBRT) at each fraction on the 1.5T MR-Linac.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At the Sunnybrook Odette Cancer Centre (OCC), stereotactic body radiation therapy (SBRT) (35- 50 Gy in 5 fractions delivered 2x/week) has been employed in a subgroup of palliative Head and Neck cancer (HNC) patients, as part of an institutional protocol, when greater tumor response is desirable when compared to more palliative regimens.

The MR-Linac has been approved by Health Canada for radiation treatment. With superior soft tissue contrast and the possibility for daily plan adaptation, it allows for higher treatment precision delivery, improved target coverage and greater normal tissue sparing.

As a first step, this study will evaluate the feasibility and safety of using the 1.5T MR-Linac on patients with HNC who are treated with SBRT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Head and neck cancer

In this arm patients with head and neck cancers treated with SBRT are recruited.

Group Type EXPERIMENTAL

SBRT on the MR-Linac

Intervention Type RADIATION

Radiotherapy is performed on the 1.5 T MR Linac

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SBRT on the MR-Linac

Radiotherapy is performed on the 1.5 T MR Linac

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years and older
* Karnofsky performance status score of ≥70
* Biopsy-proven oligometastatic cancer to the HN
* Biopsy-proven primary HN cancer (either mucosal, nodal, skin)
* Patients deemed unsuitable by the treating radiation oncologist for radiation treatment with curative intent owing to advanced age, significant comorbidities, poor performance status, distant metastatic disease.
* ≥ 1 site amenable to HN SBRT
* Capable of providing informed consent
* Required to complete any systemic therapy ≥ 10 days prior to planned start of HN SBRT, with no plans to initiate systemic therapy ≥10 days following completion of HN SBRT.

Exclusion Criteria

* History of radiation within the projected treatment field
* Contraindications to MR imaging per institutional policy
* Patients with connective tissue disorders
* History of severe claustrophobia
* Pregnant and or breastfeeding females
* Having an estimated glomerular filtration rate (GFR) \<40 ml/min/1.73m2
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Irene Karam

Radiation Oncologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Irene Karam

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Centre

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Madette Galapin

Role: CONTACT

(416) 480-6100 ext. 89638

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1509

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
NCT06137274 ACTIVE_NOT_RECRUITING PHASE2